Following promising data regarding a 100% DCR with the combination of selective GLS1 inhibitor CB-839 and everolimus in a phase I trial in ccRCC patients [38], a randomized, double-blind, placebo-controlled phase II trial of everolimus with or without CB-839 in advanced or mRCC patients has recently completed its accrual, and the results are awaited ([NCT 03163667). The gene discussed is GLS; the disease is nonpapillary renal cell carcinoma.